Citations

Showing 10 of 108094 citations.

The Impact of Age at Time of Ileal Pouch Anal Anastomosis on Short and Long-Term Outcomes in Adults
McKenna, Nicholas P. , Mathis, Kellie L. , Pembérton, John H., Lightner, Amy L. , McKenna, Nicholas P

Mayo Clinic

Inflammatory Bowel Diseases | April 26, 2018 | Volume: 24 | Issue: 8 | Pages: 1857-1865

10.1093/ibd/izy087 | PMID 29718243 Get It

Influence of the Vibralung Acoustical Percussor on pulmonary function and sputum expectoration in individuals with cystic fibrosis
Wheatley, Courtney M. , Baker, Sarah E. , Daines, C, Phan, Hanna , Martínez, Marina González, Snyder, Eric M., Wheatley-Guy, Courtney M , Morgan, Wayne J. , Baker, Sarah E

Mayo Clinic

Therapeutic Advances in Respiratory Disease | April 26, 2018 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/1753466618770997 | PMID 29697011 Get It

Background: The Vibralung Acoustical Percussor is a new airway clearance therapy (ACT) utilizing intrapulmonary sound waves in addition to positive expiratory pressure (PEP). We evaluated the safety of the Vibralung and collected preliminary data on its ability to mediate sputum expectoration in individuals with cystic fibrosis (CF). Methods: Over two separate studies, 10 and 11 mild to moderate CF patients were recruited for study I and II, respectively. Study I: Vibralung was used for 20 min with either no sound (NS: PEP only) or sound (S: PEP and sound) on randomized visits. Pulmonary function, diffusion capacity of the lungs for carbon monoxide and nitric oxide (DLCO/DLNO), symptoms, and peripheral oxygen saturation (SpO2) were measured at baseline and at 1 and 4 h post treatment. Expectorated sputum was collected over 4 h post treatment. Study II: over 5 days of in-hospital therapy, the Vibralung or vibratory vest therapy (Vest) were used for two therapy sessions per day, with sputum collected for 20 min following each therapy and pulmonary function accessed pre and post each 5-day period (days 1–5 or 7–11) in a randomized crossover design. Results: Vibralung usage resulted in no change from baseline to 4 h post in pulmonary function, SpO2 or symptoms ( p > 0.05). At 4 h post therapy, the DLCO- and DLNO-derived measure of alveolar–capillary unit function (DM/ VC) showed improvement (DM/ VC = 12.5 ± 5.5 versus 7.3 ± 18.8% change, S versus NS) with no difference between S and NS ( p = 0.74). Sputum expectoration was similar between S and NS conditions (wet sputum = 10.5 ± 4.6 versus 9.9 ± 3.2 g, S versus NS, p = 0.25). There were no differences in the improvement in pulmonary function between Vibralung and Vest during either 5-day period during the hospital stay. Conclusions: Vibralung was well tolerated and caused no detrimental changes in pulmonary function metrics. The Vibralung appears to be a safe ACT in individuals with CF.
Ventricular Electrical Activation Delay and High-Frequency Electrocardiograms
Killu, Ammar M. , Cha, Yong‐Mei

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | April 26, 2018 | Volume: 11 | Issue: 5 | Pages: No page available

10.1161/circep.118.006396 | PMID 29700059 Get It

A Phase‐by‐Phase Review of Migraine Pathophysiology
Dodick, David W.

Mayo Clinic

Headache: The Journal of Head and Face Pain | April 26, 2018 | Volume: 58 | Issue: S1 | Pages: 4-16

10.1111/head.13300 | PMID 29697154 Get It

Migraine is a common, disabling neurological disorder characterized by multiple phases: premonitory, aura, headache, postdrome, and interictal. Our understanding of the pathophysiology of each phase of migraine has evolved over recent years. The premonitory phase begins as early as 3 days before the headache phase, and involves a complex interplay between various cortical and subcortical brain regions, including the hypothalamus and brainstem nuclei that modulate nociceptive signaling. The headache phase involves activation of the trigeminovascular system, a pathway that is well characterized. In one‐third of patients, an aura phase may occur during some attacks and likely correlates with a cortical spreading depression‐like event; a slowly propagating wave of neuronal and glial cell depolarization and hyperpolarization. Improved characterization of the pathophysiological processes involved at each stage of the migraine attack will aid the identification of new therapeutic targets for migraine prevention. This review provides an update on prevailing concepts of migraine pathophysiology.
Interobserver and intraobserver comparison of imaging glenoid morphology, glenoid version and humeral head subluxation
Cagle, Paul J. , Werner, Birgit , Shukla, Dave R. , London, Daniel A. , Parsons, Bradford O. , Millar, Neal L. , Shukla, Dave R.

Mayo Clinic

Shoulder & Elbow | April 26, 2018 | Volume: 11 | Issue: 3 | Pages: 204-209

10.1177/1758573218768507 | PMID 31210792 Get It

Background Glenoid morphology, glenoid version and humeral head subluxation represent important parameters for the treating physician. The most common method of assessing glenoid morphology is the Walch classification which has only been validated with computed tomography (CT). Methods CT images and magnetic resonance imaging (MRI) images of 25 patients were de-identified and randomized. Three reviewers assessed the images for each parameter twice. The Walch classification was assessed with a weighted kappa value. Glenoid version and humeral head subluxation were comparted with a reproducibility coefficient. Results The Walch classification demonstrated almost perfect intraobserver agreement for MRI and CT images (k = 0.87). Weighted interobserver agreement values for the Walch classification were fair for CT and MRI (k = 0.34). The weighted reproducibility coefficient for glenoid version measured 9.13 (CI 7.16–12.60) degrees for CT and 13.44 (CI 10.54–18.55) degrees for MRI images. The weighted reproducibility coefficient for percentage of humeral head subluxation was 17.43% (CI 13.67–24.06) for CT and 18.49% (CI 14.5–25.52) for MRI images. Discussion CT and MRI images demonstrated similar efficacy in classifying glenoid morphology, measuring glenoid version and measuring posterior humeral head subluxation. MRI can be used as an alternative to CT for measuring these parameters.
Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis
Ma, Christopher , Guizzetti, Leonardo , Pai, Rish K. , Parker, Claire E. , Nguyen, Tran M , Khanna, Reena , Casteele, Niels Vande , D’Haens, Geert , Sandborn, William J. , Feagan, Brian G. , Ma, C , Guizzetti, L , Fedorak, R N , Pai, R K , Vande Casteele, N , D'Haens, G , Sandborn, W J , Feagan, B G , Jairath, V , Panaccione, Remo , Fedorak, Richard N. , Jairath, Vipul

Mayo Clinic

Alimentary Pharmacology & Therapeutics | April 26, 2018 | Volume: 47 | Issue: 12 | Pages: 1578-1596

10.1111/apt.14672 | PMID 29696670 Get It

Summary Background Regulatory requirements for claims of mucosal healing in ulcerative colitis ( UC ) will require demonstration of both endoscopic and histologic healing. Quantifying these rates is essential for future drug development. Aims To meta‐analyse endoscopic and histologic placebo response and remission rates in UC randomised controlled trials ( RCT s) and identify factors influencing these rates. Methods MEDLINE , EMBASE and the Cochrane Library were searched from inception to March 2017 for placebo‐controlled trials of pharmacological interventions for UC . Endoscopic and histologic placebo rates were pooled by random effects. Mixed effects univariable and multivariable meta‐regression was used to evaluate the influence of patient, intervention and trial‐related study‐level covariates on these rates. Results Fifty‐six induction (placebo n = 4171) and 8 maintenance trials (placebo n = 1011) were included. Pooled placebo endoscopic remission and response rates for induction trials were 23% [95 confidence interval ( CI ) 19‐28%] and 35% [95% CI 27‐42%] respectively, and 20% [95% CI 16‐24%] for maintenance of remission. The pooled histologic placebo remission rate was 14% [95% CI 8‐22%] for induction trials. High heterogeneity was observed for all outcomes ( I 2 56.2%‐88.3%). On multivariable meta‐regression, central endoscopy reading was associated with significantly lower endoscopic placebo remission rates (16% vs 25%; OR = 0.52, [95% CI 0.29‐0.92], P = 0.03). On univariable meta‐regression, higher histologic placebo remission was associated with concomitant corticosteroids ( OR = 1.17 [95% CI 1.08‐1.26], P < 0.0001, per 10% increase in corticosteroid use). Conclusions Placebo endoscopic and histologic rates range from 14% to 35% in UC RCT s but are highly heterogeneous. Outcome standardisation may reduce heterogeneity and is needed in this field.
Utilization and Cost Analysis of Lung Transplantation and Survival After 10 Years of Adapting the Lung Allocation Score
Keller, Cesar A., Gonwa, Thomas A., White, Launia J. , Rucci, March, Visscher, Sue L. , Kennedy, Cassie C. , Daly, Richard C. , Naessens, James M. , Rucci, March E, Kennedy, Cassie C

Mayo Clinic

Transplantation | April 25, 2018 | Volume: 103 | Issue: 3 | Pages: 638-646

10.1097/tp.0000000000002227 | PMID 29697575 Get It

Background. Lungs are allocated in the United States using the lung allocation score (LAS). We investigated the effect of LAS trends on lung transplant-related costs, healthcare utilization, and mortality. Methods. Utilization data from Mayo Clinic (Florida and Minnesota) from 2005 to 2015 were obtained from the electronic health records (N = 465). Costs were categorized as 1-year posttransplant or transplant episode and standardized using 2015 Medicare reimbursement and cost-to-charge ratios. Regression analysis was used to assess the relationship of LAS to length of stay (LOS), mortality, and cost of transplant. Results. The mean LAS at transplant increased from 45.7 to 58.3 during the study period, whereas the 1-year survival improved from 88.1% to 92.5% (P < 0.0001). The proportion of patients transplanted with LAS of 60 or greater increased from 16.9% to 33.3%. Posttransplant, overall, and intensive care unit LOS increased with increasing LAS. Patients with higher LAS had substantially higher transplant episode costs. An increase of LAS at transplant by 10 points increased inflation-adjusted costs by 12.0% (95% confidence interval, 9.3%–14.5%). Conclusions. The mean LAS at transplant has significantly increased over time associated with increases in LOS, resource utilization and cost. Lung allocation score has not jeopardized overall survival, but a high LAS (>60) at transplant is associated with increased mortality.
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
Forero‐Torres, Andres , Sher, Taimur , Diefenbach, Catherine , Johnston, Patrick B. , Talpaz, Moshe , Pulini, Jennifer, Zhou, Li , Scherle, Peggy , Chen, Xuejun , Phillips, Tycel , Barr, Paul M. , Talpaz, Moshe , Diefenbach, Catherine S

Mayo Clinic

Blood | April 25, 2018 | Volume: 132 | Issue: 3 | Pages: 293-306

10.1182/blood-2017-10-812701 | PMID 29695516 Get It

Key PointsINCB040093 was active across lymphoma subtypes, and the addition of itacitinib provided substantial activity in classic Hodgkin lymphoma. INCB040093 ± itacitinib had a manageable safety and tolerability profile; severe hepatic adverse effects were less common with the combination.
Response to Trametinib of a Pulmonary Langerhans Cell Histiocytosis Harboring a MAP2K1 Deletion
Lorillon, Gwenaël, Margerie‐Mellon, Constance de , Vercellino, Laëtitia , Meignin, Véronique , Vassallo, Robert , Mourah, Samia , Tazi, Abdellatif , Vassallo, Robert , Jouenne, Fanélie , Baroudjian, Barouyr , Lebbé, Célèste

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 25, 2018 | Volume: 198 | Issue: 5 | Pages: 675-678

10.1164/rccm.201802-0275le | PMID 29694792 Get It

The Influence of Cultural Norms on Nickel Allergic Contact Dermatitis Prevalence Data
Rundle, Chandler W. , Brankov, Nikoleta, Limone, Brittanya , Jacob, Sharon E. , Bergman, Daniel A.

Mayo Clinic

Dermatitis® | April 25, 2018 | Volume: 29 | Issue: 3 | Pages: 165-166

10.1097/der.0000000000000369 | PMID 29698359 Get It